NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.27% | 5.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.27% | 5.29% | |||
| Cost of Revenue | -9.57% | 7.85% | |||
| Gross Profit | 9.33% | 4.38% | |||
| SG&A Expenses | 5.47% | 3.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.09% | 2.47% | |||
| Operating Income | -3.23% | 8.86% | |||
| Income Before Tax | -36.41% | 14.17% | |||
| Income Tax Expenses | -327.03% | 40.47% | |||
| Earnings from Continuing Operations | 34.27% | 7.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.27% | 7.15% | |||
| EBIT | -3.23% | 8.86% | |||
| EBITDA | -6.57% | 10.31% | |||
| EPS Basic | 34.44% | 7.45% | |||
| Normalized Basic EPS | -114.61% | 14.40% | |||
| EPS Diluted | 34.44% | 7.45% | |||
| Normalized Diluted EPS | -114.61% | 14.40% | |||
| Average Basic Shares Outstanding | 0.30% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.30% | 0.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||